{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T13:46:00Z","timestamp":1776692760021,"version":"3.51.2"},"reference-count":27,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"abstract":"<jats:p>Sex differences in cutaneous melanoma (CM) survival are pronounced. It is unclear how these differences impact the loss in life expectancy (LLE). A population-based cohort from the Swedish Melanoma registry was used to analyze sex differences in life expectancy (LE) and LLE following a CM diagnosis. The cohort included 12 ,893 men and 12 ,572 women aged 40 years or above diagnosed with a first invasive CM in Sweden between 2000 and 2014. The average remaining LE at CM diagnosis was 15.45 years (95% CI 15.21, 15.7) for men and 20.14 years (95% CI 19.89, 20.43) for women, and the LLE was 2.95 years (95% CI 2.70, 3.19) and 2.4 years (95% CI 2.11, 2.67), respectively. If men had the same relative survival as women, the average LE for men would instead be 17.33 years (95% CI 17.03, 17.65) and the LLE 1.07 years (95% CI 1.07, 1.38). Men lose more years due to CM than women. Baseline age, stage or location are not sufficient to explain the sex differences.<\/jats:p>","DOI":"10.2340\/actadv.v106.adv-2025-0227","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T12:57:12Z","timestamp":1776689832000},"source":"Crossref","is-referenced-by-count":0,"title":["Sex Differences in Loss in Life Expectancy in Primary Cutaneous Melanoma, a Swedish Cohort Study"],"prefix":"10.2340","volume":"106","author":[{"given":"Anna","family":"Oksanen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisavet","family":"Syriopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kari","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6728-5344","authenticated-orcid":false,"given":"Hanna","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Therese","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1183","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"150546","doi-asserted-by":"crossref","unstructured":"Joosse A, Collette S, Suciu S, Nijsten T, Lejeune F, Kleeberg UR, et al. Superior outcome of women with stage I\/II cutaneous melanoma: pooled analysis of four European Organisation for Research and Treatment of Cancer phase III trials. J Clin Oncol 2012; 30: 2240\u20132247.","DOI":"10.1200\/JCO.2011.38.0584"},{"key":"150547","doi-asserted-by":"crossref","unstructured":"Joosse A, Collette S, Suciu S, Nijsten T, Patel PM, Keilholz U, et al. Sex is an independent prognostic indicator for survival and relapse\/progression-free survival in metastasized stage III to IV melanoma: a pooled analysis of five European organisation for research and treatment of cancer randomized controlled trials. J Clin Oncol 2013; 31: 2337\u20132346.","DOI":"10.1200\/JCO.2012.44.5031"},{"key":"150548","doi-asserted-by":"crossref","unstructured":"Schwartz MR, Luo L, Berwick M. Sex differences in melanoma. Curr Epidemiol Rep 2019; 6: 112\u2013118.","DOI":"10.1007\/s40471-019-00192-7"},{"key":"150549","doi-asserted-by":"crossref","unstructured":"White LP. Studies on melanoma. II. Sex and survival in human melanoma. N Engl J Med 1959; 260: 789\u2013797.","DOI":"10.1056\/NEJM195904162601601"},{"key":"150550","doi-asserted-by":"crossref","unstructured":"Eriksson H, Lyth J, M\u00e5nsson-Brahme E, Frohm-Nilsson M, Ingvar C, Lindholm C, et al. Low level of education is associated with later stage at diagnosis and reduced survival in cutaneous malignant melanoma: a nationwide population-based study in Sweden. Eur J Cancer 2013; 49: 2705\u20132716.","DOI":"10.1016\/j.ejca.2013.03.013"},{"key":"150551","doi-asserted-by":"crossref","unstructured":"Crombie IK. Distribution of malignant melanoma on the body surface. Br J Cancer 1981; 43: 842\u2013849.","DOI":"10.1038\/bjc.1981.123"},{"key":"150552","doi-asserted-by":"crossref","unstructured":"El Sharouni MA, Witkamp AJ, Sigurdsson V, van Diest PJ, Louwman MWJ, Kukutsch NA. Sex matters: men with melanoma have a worse prognosis than women. J Eur Acad Dermatol Venereol 2019; 33: 2062\u20132067.","DOI":"10.1111\/jdv.15760"},{"key":"150553","doi-asserted-by":"crossref","unstructured":"Andersson TML, Eriksson H, Hansson J, M\u00e5nsson-Brahme E, Dickman PW, Eloranta S, et al. Estimating the cure proportion of malignant melanoma, an alternative approach to assess long term survival: a population-based study. Cancer Epidemiol 2014; 38: 93\u201399.","DOI":"10.1016\/j.canep.2013.12.006"},{"key":"150554","unstructured":"Swedish melanoma registry (SweMR\u2013Svenska Melanomregistret). 2025 Feb 13. Available from: Https:\/\/ Cancercentrum.Se\/Samverkan\/Cancerdiagnoser\/Hud-Och- Melanom\/Malignt-Melanom\/Kvalitetsregister\/"},{"key":"150555","doi-asserted-by":"crossref","unstructured":"Andersson TML, Dickman PW, Eloranta S, Lambe M, Lambert PC. Estimating the loss in expectation of life due to cancer using flexible parametric survival models. Stat Med 2013; 32: 5286\u20135300.","DOI":"10.1002\/sim.5943"},{"key":"150556","doi-asserted-by":"crossref","unstructured":"JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017; 67: 472\u2013492.","DOI":"10.3322\/caac.21409"},{"key":"150557","doi-asserted-by":"crossref","unstructured":"Vikstr\u00f6m S, Syriopoulou E, Andersson TML, Eriksson H. Loss in life expectancy in patients with stage II-III cutaneous melanoma in Sweden: a population-based cohort study. J Am Acad Dermatol 2024; 90: 963\u2013969.","DOI":"10.1016\/j.jaad.2023.12.053"},{"key":"150558","doi-asserted-by":"crossref","unstructured":"Syriopoulou E, Bower H, Andersson TML, Lambert PC, Rutherford MJ. Estimating the impact of a cancer diagnosis on life expectancy by socio-economic group for a range of cancer types in England. Br J Cancer 2017; 117: 1419\u20131426.","DOI":"10.1038\/bjc.2017.300"},{"key":"150559","doi-asserted-by":"crossref","unstructured":"Thiam A, Zhao Z, Quinn C, Barber B. Years of life lost due to metastatic melanoma in 12 countries. J Med Econ 2016; 19: 259\u2013264.","DOI":"10.3111\/13696998.2015.1115764"},{"key":"150560","doi-asserted-by":"crossref","unstructured":"Jung KW, Park S, Shin A, Oh CM, Kong HJ, Jun JK, et al. Do female cancer patients display better survival rates compared with males? Analysis of the Korean National Registry data, 2005-2009. PLoS One 2012; 7: e52457.","DOI":"10.1371\/journal.pone.0052457"},{"key":"150561","doi-asserted-by":"crossref","unstructured":"Magnus K. Prognosis in malignant melanoma of the skin. Significance of stage of disease, anatomical site, sex, age and period of diagnosis. Cancer 1977; 40: 389\u2013397.","DOI":"10.1002\/1097-0142(197707)40:1<389::AID-CNCR2820400155>3.0.CO;2-I"},{"key":"150562","doi-asserted-by":"crossref","unstructured":"Rampen FHJ. Sex differences in survival from cutaneous melanoma. Int J Dermatology 1984; 23: 444\u2013452.","DOI":"10.1111\/ijd.1984.23.7.444"},{"key":"150563","doi-asserted-by":"crossref","unstructured":"Malec E, Eklund G. The changing incidence of malignant melanoma of the skin in Sweden, 1959-1968. Scand J Plast Reconstr Surg 1978; 12: 19\u201327.","DOI":"10.3109\/02844317809010476"},{"key":"150564","doi-asserted-by":"crossref","unstructured":"Olsen CM, Thompson JF, Pandeya N, Whiteman DC. Evaluation of sex-specific incidence of melanoma. JAMA Dermatol 2020; 156: 553\u2013560.","DOI":"10.1001\/jamadermatol.2020.0470"},{"key":"150565","doi-asserted-by":"crossref","unstructured":"Shaw HM, McGovern VJ, Milton GW, Farago GA, McCarthy WH. Histologic features of tumors and the female superiority in survival from malignant melanoma. Cancer 1980; 45: 1604\u20131608.","DOI":"10.1002\/1097-0142(19800401)45:7<1604::AID-CNCR2820450715>3.0.CO;2-O"},{"key":"150566","doi-asserted-by":"crossref","unstructured":"Smith AJ, Lambert PC, Rutherford MJ. Understanding the impact of sex and stage differences on melanoma cancer patient survival: a SEER-based study. Br J Cancer 2021; 124: 671\u2013677.","DOI":"10.1038\/s41416-020-01144-5"},{"key":"150567","doi-asserted-by":"crossref","unstructured":"Yuan TA, Lu Y, Edwards K, Jakowatz J, Meyskens FL, Liu-Smith F. Race-, age-, and anatomic site-specific gender differences in cutaneous melanoma suggest differential mechanisms of early- and late-onset melanoma. Int J Environ Res Public Health 2019; 16: 908.","DOI":"10.3390\/ijerph16060908"},{"key":"150568","doi-asserted-by":"crossref","unstructured":"Cosman B, Heddle SB, Crikelair GV. The increasing incidence of melanoma. Plast Reconstr Surg 1976; 57: 50\u201356.","DOI":"10.1097\/00006534-197601000-00010"},{"key":"150569","doi-asserted-by":"crossref","unstructured":"Erdmann F, Lortet-Tieulent J, Schu\u0308z J, Zeeb H, Greinert R, Breitbart EW, et al. International trends in the incidence of malignant melanoma 1953-2008--are recent generations at higher or lower risk? Int J Cancer 2013; 132: 385\u2013400.","DOI":"10.1002\/ijc.27616"},{"key":"150570","doi-asserted-by":"crossref","unstructured":"Welch HG, Mazer BL, Adamson AS. The rapid rise in cutaneous melanoma diagnoses. N Engl J Med 2021; 384: 72\u201379.","DOI":"10.1056\/NEJMsb2019760"},{"key":"150571","doi-asserted-by":"crossref","unstructured":"Rubin R. Melanoma diagnoses rise while mortality stays fairly flat, raising concerns about overdiagnosis. JAMA 2020; 323: 1429.","DOI":"10.1001\/jama.2020.2669"},{"key":"150572","doi-asserted-by":"crossref","unstructured":"Kurtansky NR, Dusza SW, Halpern AC, Hartman RI, Geller AC, Marghoob AA, et al. An epidemiologic analysis of melanoma overdiagnosis in the United States, 1975-2017. J Invest Dermatol 2022; 142: 1804\u20131811.","DOI":"10.1016\/j.jid.2021.12.003"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/45958\/53570","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/45958\/53571","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/45958\/53572","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/45958\/53570","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T12:57:36Z","timestamp":1776689856000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/45958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":27,"URL":"https:\/\/doi.org\/10.2340\/actadv.v106.adv-2025-0227","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,20]]}}}